{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T02:52:38Z","timestamp":1794365558204,"version":"4.9.0"},"publisher-location":"Chichester, UK","reference-count":98,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd005019.pub3","type":"reference-entry","created":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T14:54:02Z","timestamp":1239807242000},"source":"Crossref","is-referenced-by-count":17,"title":["HMG CoA reductase inhibitors (statins) for kidney transplant recipients"],"prefix":"10.1002","author":[{"given":"Sankar D","family":"Navaneethan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar U","family":"Nigwekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,4,15]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD005019.pub3-BIB1|cit1","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1399-0012.2006.00555.x","article-title":"No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study","volume":"20","author":"Fellstrom","year":"2006","journal-title":"Clinical Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD005019.pub3-BIB2|cit2","first-page":"187A","article-title":"Renal transplant function as a risk factor for graft loss, cardiac disease and all cause mortality in renal transplantation - experience from the ALERT trial [abstract]","volume":"14","author":"Fellstrom","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD005019.pub3-BIB3|cit3","first-page":"10A","article-title":"Effects of fluvastatin on graft losses and renal function in renal transplantation - experience from the ALERT trial [abstract]","volume":"14","author":"Fellstrom","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD005019.pub3-BIB4|cit4","first-page":"185A","article-title":"Risk factors for graft loss or doubling of serum creatinine in renal transplantation - experience from the ALERT trial [abstract]","volume":"14","author":"Fellstrom","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD005019.pub3-BIB5|cit5","first-page":"236","article-title":"Effects of fluvastatin on renal transplant function and graft loss in renal transplant patients in ALERT (Assessment of LEscol in Renal Transplantation) [abstract]","volume":"18","author":"Fellstrom","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD005019.pub3-BIB6|cit6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.TP.0000147338.34323.12","article-title":"Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial","volume":"79","author":"Fellstrom","year":"2005","journal-title":"Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD005019.pub3-BIB7|cit7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00007890-200407271-00161","article-title":"Renal transplant function as a risk factor for cardiovascular disease and mortality and for all cause mortality in renal transplantation - experience from the ALERT trial [abstract]","volume":"78","author":"Fellstrom","year":"2004","journal-title":"Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD005019.pub3-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1111\/j.1600-6143.2005.00983.x","article-title":"Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation","volume":"5","author":"Fellstrom","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD005019.pub3-BIB9|cit9","first-page":"261","article-title":"Influence of renal transplant function on cardiovascular disease and all cause mortality in the ALERT trial [abstract]","volume":"4","author":"Fellstrom","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD005019.pub3-BIB10|cit10","first-page":"19A","article-title":"Parathyroid hormone and phosphate - risk factors for post-transplant cardiovascular disease? [abstract no: TH-FC084]","volume":"17","author":"Holdaas","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD005019.pub3-BIB11|cit11","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1600-6143.2005.01105.x","article-title":"Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study","volume":"5","author":"Holdaas","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD005019.pub3-BIB12|cit12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00043798-200104000-00002","article-title":"Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data","volume":"8","author":"Holdaas","year":"2001","journal-title":"Journal of Cardiovascular Risk"},{"issue":"Suppl","key":"10.1002\/14651858.CD005019.pub3-BIB13|cit13","first-page":"A88","article-title":"Long term effectiveness and safety of fluvastatin in renal transplant recipients: the ALERT trial follow-up [abstract]","volume":"10","author":"Holdaas","year":"2005","journal-title":"Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD005019.pub3-BIB14|cit14","first-page":"185A","article-title":"Lipid-lowering therapy should be started early in the post-transplant period [abstract]","volume":"14","author":"Holdaas","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD005019.pub3-BIB15|cit15","first-page":"v3","article-title":"Long term efficacy, safety and tolerability of fluvastatin in renal transplant recipients: the ALERT trial follow-up [abstract]","volume":"20","author":"Holdaas","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Oct","key":"10.1002\/14651858.CD005019.pub3-BIB16|cit16","first-page":"881A","article-title":"No detrimental effect of fluvastatin on renal function in diabetic renal transplant patients. [abstract]","volume":"15","author":"Holdaas","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD005019.pub3-BIB17|cit17","first-page":"527A","article-title":"Prevalence and consequences of metabolic syndrome in a renal transplant population [abstract]","volume":"15","author":"Holdaas","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD005019.pub3-BIB19|cit18","first-page":"237","article-title":"Effects of fluvastatin on cardiovascular events in renal transplant patients: ALERT (Assessment LEscol in Renal Transplantation) [abstract]","volume":"18","author":"Holdaas","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD005019.pub3-BIB18|cit19","first-page":"442","article-title":"Randomized double blind trial of fluvastatin for hypercholesterolemia in renal transplant recipients [abstract]","volume":"3","author":"Holdaas","year":"2003","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD005019.pub3-BIB20|cit20","first-page":"72A","article-title":"Long term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT Extension Study [abstract]","volume":"16","author":"Holdaas","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD005019.pub3-BIB21|cit21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00007890-200407271-00873","article-title":"No detrimental effect on renal function during long-term use of fluvastatin. [abstract]","volume":"78","author":"Holdaas","year":"2004","journal-title":"Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD005019.pub3-BIB22|cit22","first-page":"662A","article-title":"Lipids as risk factors for cardiac events after renal transplantation - experience from the ALERT trial. [abstract]","volume":"14","author":"Holdaas","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9374","key":"10.1002\/14651858.CD005019.pub3-BIB23|cit23","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD005019.pub3-BIB24|cit24","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/ndt\/gfh735","article-title":"Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation","volume":"20","author":"Holdaas","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD005019.pub3-BIB25|cit25","first-page":"231A","article-title":"Osteoprotegerin - a novel risk factor post-transplant cardiovascular disease [abstract]","volume":"17","author":"Jardine","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD005019.pub3-BIB26|cit26","first-page":"746A","article-title":"New targets for cardiovascular risk reduction in renal transplant recipients: post-hoc analyses of the ALERT study. [abstract]","volume":"15","author":"Jardine","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub3-BIB27|cit27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1053\/j.ajkd.2005.05.014","article-title":"Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study","volume":"46","author":"Jardine","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD005019.pub3-BIB28|cit28","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1600-6143.2004.00445.x","article-title":"Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study","volume":"4","author":"Jardine","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD005019.pub3-BIB29|cit29","first-page":"488","article-title":"Adverse impact of steroids on outcome in the ALERT study. [abstract]","volume":"4","author":"Jardine","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub3-BIB30|cit30","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1399-0012.2006.00496.x","article-title":"Gender-associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study","volume":"20","author":"Oien","year":"2006","journal-title":"Clinical Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD005019.pub3-BIB31|cit31","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1194\/jlr.M700076-JLR200","article-title":"Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients","volume":"48","author":"Singer","year":"2007","journal-title":"Journal of Lipid Research"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub3-BIB32|cit32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000188088","article-title":"Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients","volume":"68","author":"Arnadottir","year":"1994","journal-title":"Nephron"},{"issue":"6","key":"10.1002\/14651858.CD005019.pub3-BIB33|cit33","first-page":"1061","article-title":"Low dose lovastatin does not improve kidney allograft function during 6-month observation [abstract]","volume":"10","author":"Bill","year":"1995","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD005019.pub3-BIB34|cit34","first-page":"417","article-title":"Six-month treatment with low-dose lovastatin does not improve kidney allograft function","volume":"20","author":"Bill","year":"1995","journal-title":"Polish Journal of Immunology"},{"issue":"2","key":"10.1002\/14651858.CD005019.pub3-BIB35|cit35","first-page":"144","article-title":"The effect of hypolipidemia treatment on the function of kidney transplanted from cadavers","volume":"97","author":"Paczek","year":"1997","journal-title":"Polskie Archiwum Medycyny Wewnetznej"},{"issue":"2","key":"10.1002\/14651858.CD005019.pub3-BIB36|cit36","first-page":"65","article-title":"Non-immune factors in chronic rejection. Is there a role for hypolipemic drugs?","volume":"2","author":"Paczek","year":"1997","journal-title":"Annals of Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005019.pub3-BIB37|cit37","first-page":"S574","article-title":"Treatment with low-dose lovastatin does not improve kidney allograft function during 6-month observation [abstract]","volume":"3","author":"Paczek","year":"1997","journal-title":"Nephrology"},{"issue":"1 Pt 2","key":"10.1002\/14651858.CD005019.pub3-BIB38|cit38","first-page":"1043","article-title":"HMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation","volume":"25","author":"Castelao","year":"1993","journal-title":"Transplantation Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub3-BIB39|cit39","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0041-1345(01)02813-5","article-title":"Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients","volume":"34","author":"Cofan","year":"2002","journal-title":"Transplantation Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD005019.pub3-BIB40|cit40","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0041-1345(01)02814-7","article-title":"Pravastatin improves low-density lipoprotein oxidation in renal transplantation","volume":"34","author":"Cofan","year":"2002","journal-title":"Transplantation Proceedings"},{"key":"10.1002\/14651858.CD005019.pub3-BIB41|cit41","series-title":"XVIII International Congress of the Transplantation Society; 2000 Aug 27-Sept 1; Rome (Italy)","article-title":"A randomised controlled trial assessing the effect of fluvastatin on acute rejection rate following renal transplantation [abstract]","author":"Holdaas","year":"2000"},{"key":"10.1002\/14651858.CD005019.pub3-BIB42|cit42","doi-asserted-by":"crossref","unstructured":"Holdaas H Jardine AG Wheeler DC Brekke IB Conlon PJ Fellstrom B Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial Kidney International 2001 1990 7 21561172","DOI":"10.1046\/j.1523-1755.2001.00010.x"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD005019.pub3-BIB44|cit43","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1097\/00007890-200004271-00429","article-title":"Effects of lipid reduction on acute renal allograft rejection [abstract]","volume":"69","author":"Kasiske","year":"2000","journal-title":"Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD005019.pub3-BIB43|cit44","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00007890-200107270-00009","article-title":"The effects of lipid-lowering agents on acute renal allograft rejection","volume":"72","author":"Kasiske","year":"2001","journal-title":"Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub3-BIB45|cit45","first-page":"1017","article-title":"Pravastatin lowers natural killer cell cytotoxicity and decreases the incidence of early acute rejection episodes in renal transplant patients [abstract]","volume":"5","author":"Katznelson","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD005019.pub3-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1097\/00007890-199605270-00010","article-title":"The effect of pravastatin on acute rejection after kidney transplantation--a pilot study","volume":"61","author":"Katznelson","year":"1996","journal-title":"Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD005019.pub3-BIB47|cit47","doi-asserted-by":"crossref","first-page":"577","DOI":"10.5414\/NHP33577","article-title":"Sustained beneficial effect of a therapy with the HMG-Co-A-reductase inhibitor fluvastatin on endothelial function in renal transplant recipients","volume":"33","author":"Kosch","year":"2004","journal-title":"Nieren-und Hochdruckkrankheiten"},{"issue":"5","key":"10.1002\/14651858.CD005019.pub3-BIB48|cit48","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0272-6386(03)00207-5","article-title":"Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient","volume":"41","author":"Kosch","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD005019.pub3-BIB49|cit49","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1034\/j.1399-0012.1999.130613.x","article-title":"A double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients","volume":"13","author":"Lepre","year":"1999","journal-title":"Clinical Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub3-BIB51|cit50","first-page":"869","article-title":"Low dose simvastatin (ls) is safe in hyperlipidemic transplant patients treated with CyA [abstract]","volume":"3","author":"Martinez-Hernandez","year":"1992","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD005019.pub3-BIB50|cit51","first-page":"637","article-title":"Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients","volume":"8","author":"Martinez Hernandez","year":"1993","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub3-BIB52|cit52","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/ndt\/16.1.141","article-title":"Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients","volume":"16","author":"Renders","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub3-BIB53|cit53","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1034\/j.1399-0012.2001.150305.x","article-title":"Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection","volume":"15","author":"Sahu","year":"2001","journal-title":"Clinical Transplantation"},{"key":"10.1002\/14651858.CD005019.pub3-BIB54|cit54","series-title":"A Transplant Odyssey; 2001 Aug 20-23; Istanbul, Turkey","article-title":"Is cyclosporin microemulsion increasing the lipid-lowering effect of simvastatin on kidney graft receptors? [abstract]","author":"Garcia","year":"2001"},{"key":"10.1002\/14651858.CD005019.pub3-BIB55|cit55","series-title":"A Transplant Odyssey; 2001 Aug 20-23; Istanbul, Turkey","article-title":"Is simvastatin able to reduce the plasma levels of fibrinogen in kidney graft receptors? a double-blind, randomized placebo controlled study [abstract]","author":"Garcia","year":"2001"},{"key":"10.1002\/14651858.CD005019.pub3-BIB56|cit56","series-title":"XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami, FL","article-title":"Is cyclosporin microemulsion increasing the lipid-lowering effect of simvastatin on kidney graft receptor? [abstract]","author":"Santos","year":"2002"},{"key":"10.1002\/14651858.CD005019.pub3-BIB57|cit57","series-title":"XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami, FL","article-title":"Is simvastatin able to reduce the plasma levels of fibrinogen in kidney graft receptors? A double-blind randomized placebo controlled study [abstract]","author":"Santos","year":"2002"},{"key":"10.1002\/14651858.CD005019.pub3-BIB59|cit58","series-title":"XVIII International Congress of the Transplantation Society; 2000 Aug 27-Sept 1; Rome, Italy","article-title":"Treatment of hyperlipidemia in renal transplant recipients with simvastatin: a double-blind, randomized, placebo-controlled study [abstract]","author":"Santos","year":"2000"},{"issue":"1-2","key":"10.1002\/14651858.CD005019.pub3-BIB58|cit59","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S0041-1345(00)02382-4","article-title":"Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study","volume":"33","author":"Santos","year":"2001","journal-title":"Transplantation Proceedings"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub3-BIB60|cit60","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0041-1345(00)00921-0","article-title":"Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients","volume":"32","author":"Tuncer","year":"2000","journal-title":"Transplantation Proceedings"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub3-BIB61|cit61","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.ajkd.2004.11.015","article-title":"First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease","volume":"45","author":"Baigent","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"issue":"September, Prog","key":"10.1002\/14651858.CD005019.pub3-BIB62|cit62","first-page":"437a","article-title":"Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract]","volume":"13","author":"Baigent","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub3-BIB63|cit63","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/ndt\/14.3.648","article-title":"Cardiovascular morbidity and risk factors in renal transplant patients","volume":"14","author":"Aakhus","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD005019.pub3-BIB64|cit64","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/BF02564867","article-title":"Cardiovascular risk factors and diseases after renal transplantation","volume":"30","author":"Aker","year":"1998","journal-title":"International Urology & Nephrology"},{"issue":"23","key":"10.1002\/14651858.CD005019.pub3-BIB65|cit65","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","article-title":"Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)","volume":"288","year":"2002","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD005019.pub3-BIB66|cit66","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1034\/j.1399-0012.2003.00063.x","article-title":"Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation","volume":"17","author":"Asberg","year":"2003","journal-title":"Clinical Transplantation"},{"issue":"10","key":"10.1002\/14651858.CD005019.pub3-BIB67|cit67","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1093\/ndt\/12.10.2140","article-title":"Therapy of post renal transplantation hyperlipidemia: comparative study with simvastatin and fish oil","volume":"12","author":"Castro","year":"1997","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD005019.pub3-BIB68|cit68","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0041-1345(98)00246-2","article-title":"Lipoprotein patterns in renal transplant patients: a comparison between FK506 and cyclosporine A patients","volume":"30","author":"Claesson","year":"1998","journal-title":"Transplantation Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub3-BIB69|cit69","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0021-9150(93)90107-6","article-title":"Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase","volume":"10","author":"Corsini","year":"1993","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub3-BIB70|cit70","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/ajkd.2002.34927","article-title":"Patient survival after renal transplantation III: the effects of statins","volume":"40","author":"Cosio","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD005019.pub3-BIB71|cit71","first-page":"iii67","article-title":"The effects of hyperlipidaemia on graft and patient outcome in renal transplantation","volume":"19","author":"Castillo","year":"2004","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD005019.pub3-BIB72|cit72","first-page":"26","article-title":"European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.3. Cardiovascular risks. Hyperlipidaemia","volume":"17","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD005019.pub3-BIB73|cit73","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/j.1523-1755.2004.00919.x","article-title":"Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial","volume":"66","author":"Fellstr\u00f6m","year":"2004","journal-title":"Kidney International"},{"issue":"8","key":"10.1002\/14651858.CD005019.pub3-BIB74|cit74","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/00007890-200210270-00002","article-title":"Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine","volume":"74","author":"Flechner","year":"2002","journal-title":"Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD005019.pub3-BIB75|cit75","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","article-title":"Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group","volume":"67","author":"Groth","year":"1999","journal-title":"Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD005019.pub3-BIB76|cit76","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1046\/j.1523-1755.2001.0590041473.x","article-title":"Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation","volume":"59","author":"Hausberg","year":"2001","journal-title":"Kidney International"},{"issue":"12","key":"10.1002\/14651858.CD005019.pub3-BIB77|cit77","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1681\/ASN.V5122073","article-title":"The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients","volume":"5","author":"Hilbrands","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9374","key":"10.1002\/14651858.CD005019.pub3-BIB78|cit78","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub3-BIB79|cit79","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00007890-199401000-00013","article-title":"Risk factors predicting chronic rejection of renal allografts","volume":"57","author":"Isoniemi","year":"1994","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub3-BIB80|cit80","first-page":"14","article-title":"The effect of cyclosporine A on plasma lipids during the first year after transplantation","volume":"12","author":"John","year":"1999","journal-title":"National Medical Journal of India"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub3-BIB81|cit81","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1681\/ASN.V71158","article-title":"Cardiovascular disease after renal transplantation","volume":"7","author":"Kasiske","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD005019.pub3-BIB82|cit82","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-6135.2004.0355.x","article-title":"Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative","volume":"4","author":"Kasiske","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub3-BIB83|cit83","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0162-3109(96)00108-7","article-title":"Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro","volume":"34","author":"Kurakata","year":"1996","journal-title":"Immunopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD005019.pub3-BIB84|cit84","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/0272-6386(95)90133-7","article-title":"Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial","volume":"25","author":"Lal","year":"1995","journal-title":"American Journal of Kidney Diseases"},{"issue":"9","key":"10.1002\/14651858.CD005019.pub3-BIB85|cit85","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1093\/ndt\/gfh385","article-title":"Statin use after renal transplantation: a systematic quality review of trial-based evidence","volume":"19","author":"Lentine","year":"2004","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"8994","key":"10.1002\/14651858.CD005019.pub3-BIB86|cit86","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0140-6736(96)90217-2","article-title":"Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?","volume":"347","author":"Massy","year":"1996","journal-title":"Lancet"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD005019.pub3-BIB87|cit87","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/00007890-200109271-00005","article-title":"Hyperlipidemia and cardiovascular disease after organ transplantation","volume":"72","author":"Massy","year":"2001","journal-title":"Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD005019.pub3-BIB88|cit88","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/ajhp\/61.6.565","article-title":"Drug-related dyslipidemia after renal transplantation","volume":"61","author":"Mathis","year":"2004","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"5","key":"10.1002\/14651858.CD005019.pub3-BIB89|cit89","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.transproceed.2004.05.036","article-title":"Metaanalysis of statins and survival in de novo cardiac transplantation","volume":"36","author":"Mehra","year":"2004","journal-title":"Transplantation Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD005019.pub3-BIB90|cit90","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification and stratification","volume":"39","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD005019.pub3-BIB91|cit91","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/oxfordjournals.ndt.a091698","article-title":"Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients","volume":"3","author":"Raine","year":"1988","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub3-BIB92|cit92","first-page":"49","article-title":"Treatment of hyperlipidemia after renal transplantation: Comparative effect of lovastatin and omega-3 fatty acids","volume":"17","author":"Rodriguez","year":"1997","journal-title":"Nefrologia"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub3-BIB93|cit93","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/00007890-199802150-00030","article-title":"Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine","volume":"65","author":"Satterthwaite","year":"1998","journal-title":"Transplantation"},{"issue":"9364","key":"10.1002\/14651858.CD005019.pub3-BIB94|cit94","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"issue":"20","key":"10.1002\/14651858.CD005019.pub3-BIB95|cit95","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study","volume":"333","author":"Shepherd","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"6 Suppl 5","key":"10.1002\/14651858.CD005019.pub3-BIB96|cit96","first-page":"1","article-title":"The United States Renal Data System","volume":"42","author":"USRDS","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub3-BIB97|cit97","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00007890-198907000-00009","article-title":"Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients","volume":"48","author":"Vathsala","year":"1989","journal-title":"Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD005019.pub3-BIB98|cit98","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005019","article-title":"HMG CoA reductase inhibitors (statins) for kidney transplant patients [Protocol]","author":"Perkovic","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd005019.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T00:00:00Z","timestamp":1390780800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD005019.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T01:12:14Z","timestamp":1633309934000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD005019.pub3"}},"subtitle":[],"editor":[{"given":"Sankar D","family":"Navaneethan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2009,4,15]]},"references-count":98,"aliases":["10.1002\/14651858.cd005019.pub2"],"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005019.pub3","relation":{},"subject":[],"published":{"date-parts":[[2009,4,15]]}}}